Kymera Investor Day Presentation Deck
MDM2 Dependency Seen Across a Large Subset of Tumor Types
Large Franchise Potential in Liquid and Solid Tumors
MDM2 CRISPR Sensitivity Score
0.6
0.4
0.2
0
-0.2
-0.4
-0.6
-0.8
-1
-1.2
-1.4
-1.6
-1.8
-2
-2.2
Dependency of p53WT Cell Lines
on MDM2
p53MUT
p53WT
Graph generated with data obtained from DepMap.org
Cell Line
Tumor Types: Uveal melanoma, Bile Duct, Bladder, Bone, Brain, Breast,
Colon, Endometrial/Uterine, Gastric, Kidney, Liver, Lung, Ovarian,
Pancreatic, Rhabdoid, Sarcoma, Leukemia, Lymphoma
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
% Growth Inhibition (CTG)
MDM2 Degrader Superior to SMI
Across Cell Line Panel
Heme & Solid Cell Lines
100
80
60
40
20
O
-20
0.00001
KT-253
DS-3032
KYMERA R&D DAY - December 16th, 2021
0.0001
0.001
0.01
0.1
DMSO
10
Concentration, μM
p53WT cell lines sensitive: ALL, AML, DLBCL, Uveal Melanoma
p53 mutant cell lines were not sensitive to KT-253 or DS-3032 as
expected
PAGE 82View entire presentation